Fedratinib: The selective JAK2 inhibitor fedratinib was reported to provide clinical benefit in patients with ruxolitinib‐resistant or ruxolitinib‐intolerant myelofibrosis.[549] In addition, for ruxolitinib‐resistant or ruxolitinib‐intolerant patients, pan‐JAK inhibitors of JAK1, JAK2, JAK3, and TYK2 might be another option, and phase II clinical trials are ongoing to further confirm their efficacy.[550, 551]. This evidence concerns the gene JAK2 and myelofibrosis.